SP1 and breast carcinoma: Our findings are interpreted to show that SP-1-303 exhibits toxicity preferentially against ER+ breast cancer cells when compared to normal breast epithelial cells (MCF10A) and triple-negative breast cancer cells (HCC1937 and MDA-MB-231).